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1. Introduction 
The body is composed of various types of cells that unite in harmony to live in the natural 
environment. Viral infections, toxic products, and environmental stresses may affect the 
cells to initiate transformation for the development of tumors, an uncontrollable and 
unfavorable state of cells. Such a tumor state of cells is closely watched by the internal 
immune-surveillance system that generally controls or eliminates them to maintain the 
harmony of the body.  
The internal immune-surveillance system is composed of two distinct parts; an innate 
immune system predominantly located on the surface areas of the body, such as the skin or 
mucosal compartments, and an acquired/adaptive immune system found mainly in 
systemic compartments, including circulating blood, lymph nodes, spleen, and various 
organs (Medzhitov and Janeway, 1997a) (Fig. 1). The cells of the innate immune system find 
and fight foreign bodies intruding from the outside, such as viruses and bacteria, through 
their pattern-recognition receptors (PRRs) (Medzhitov, 2007), such as Toll-like receptors 
(TLRs) (Akira et al., 2001) and C-type lectin receptors (CLRs) that recognize pathogen-
associated molecular patterns (PAMPs) (Medzhitov and Janeway, 1997b), although they do 
not have any specific memories of foreign bodies. In contrast, the acquired immune system 
will respond to foreign elements only when competent cells of the acquired system 
recognize them specifically through their receptors established via gene-rearrangements 
(Palm and Medzhitov, 2009). Among these acquired receptors, a T-cell receptor (TCR) can 
specifically recognize foreign antigens as a specific structural component composed of 
protein-derived amino acids presented particularly by self-restricted antigen-presenting 
molecules, termed major histocompatibility complex (MHC) (Takahashi, 2003) 
Although the precise mechanisms remain to be elucidated, such specific memories mediated 
through TCRs are instructed by innate cells, particularly dendritic cells (DCs), which are key 
cells to present antigenic information though their MHC together with co-stimulatory 
molecules that will promote memory formation via gene-rearrangements in acquired T cells. 
Therefore, innate DCs have the ability to capture tumor-derived antigens, processed them 
into antigenic fragments, and present the antigenic fragments in association with their MHC 
and co-stimulation molecules (Azuma et al., 1993; Chen et al., 1992), such as B7-1 (CD80), 
B7-2 (CD86), or CD40, to establish TCR-mediated antigen-specific memories in acquired 
immunity (Fig. 2). 
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Fig. 1. Innate immunity and acquired immunity. 
 
 
Fig. 2. Antigen selection and presentation by innate DCs to acquired T cells. 
Two distinct MHC molecules are expressed on the surface of antigen-presenting cells, class I 
and class II MHC. In general, class I MHC molecules can present processed fragments of 
internally produced tumor-gene or virus-gene-derived antigens to CD8+ T cells, whereas 
class II MHC present processed fragments of externally captured antigens to CD4+ T cells 
(Takahashi, 1993) (Fig. 3).  
Among TCR-mediated specific acquired immunity, class I MHC molecule-restricted tumor-
peptide-specific immunity by CD8+ cytotoxic T lymphocytes (CTLs) is particularly important 
in the elimination of tumor cells and both class I MHC molecule-associated antigenic 
stimulation and co-stimulatory signals on the same antigen-presenting cells (APCs) are 
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required to elicit such CD8+ CTLs; however, in general, tumor cells that present tumor-derived 
antigenic peptides in association with their class I MHC do not express appropriate co-
stimulation molecules and thus they cannot induce tumor-specific CD8+ CTLs. 
 
Fig. 3. Two distinct antigen presentation pathways mediated in DCs via class I and class II 
MHC molecules. 
In addition, DCs will not usually become tumor cells and thus are unable to present tumor 
antigens in conjunction with their class I MHC, despite expressing suitable co-stimulation 
molecules for the elicitation of tumor-specific CD8+ CTLs. 
On the basis of our recent findings (Moriya et al., 2010), this chapter propose a new direction 
for the establishment of tumor immunotherapy to generate tumor-derived epitope-specific 
class I MHC molecule-restricted acquired CD8+ CTLs against tumors by selective activation 
of DEC-205+ DCs that have the ability to process and cross-present antigenic fragments from 
externally captured tumor-derived products via class I MHC as well as innate effectors such 
as NKT cells and  T cells through their CD1 molecules (Takahashi, 2010). 
2. Innate and acquired effectors against tumor cells 
Tumor cells originate from normal functional cells, like melanoma from melanocytes, via 
several transformation steps, which can be classified into two types; early transformation 
steps initiated by stress-related substances and late transformation steps that generate 
mutated genes to gain uncontrollable proliferative capacity. The stress-associated products 
are expressed on the cell surface in association with MHC class I chain-related A (MICA) 
and MICB molecules, which are composed of a similar structural pattern of class I MHC. 
These MICA/MICB-associated compounds are recognized by NK group 2D (NKG2D) 
receptors of activated innate effectors, such as natural killer (NK) cells, natural killer T 
(NKT) cells, and T cells, bearing invariant receptors produced without gene-
rearrangements (Higuchi et al., 2009). These innate effectors recognize early transformed 
tumors via NKG2D receptors and eliminate them. Also, MICA/MICB expressing tumor 
cells usually show down-modulation of class I MHC that will stimulate NK cells to 
eliminate them (Suarez-Alvarez et al., 2009). 
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In contrast, mature tumor cells with mutated genes and expressing tumor-gene-encoded 
antigenic peptides on their surface in association with class I MHC molecules can be 
specifically recognized and eliminated by acquired CD8+ CTLs. Thus, stress-associated early 
transformed tumor cells appear to be regulated mainly by innate effectors, while mature 
tumor cells with specific structural mutations with high proliferative capacity can be 
specifically controlled by acquired CD8+ CTLs in a class I MHC molecule-restricted manner. 
Taken together, internally transformed tumor cells gained uncontrollable proliferating 
capacity can be recognized and regulated by both innate and acquired effectors (Fig. 4). 
 
 
Fig. 4. Immune control of immature and mature tumor cells. 
3. Antigen-presenting molecules on DCs 
Induction of these innate and acquired effectors seems to be regulated by DCs via various 
antigen-presenting molecules. Innate immunity is chiefly regulated via species-restricted 
CD1 antigen-presenting molecules and acquired immunity is controlled via individually 
restricted MHC molecules on DCs. CD1 molecules are further divided into four classes, 
CD1a, CD1b, CD1c, and CD1d. These CD1s have been found to present lipid/glycolipid 
antigens to T cells bearing relatively invariant T-cell receptors (TCR), most of which are 
conserved among species (Barral and Brenner, 2007; Cohen et al., 2009). For example, highly 
conserved CD1d molecules present -galactosyl ceramide (-GalCer) to NKT cells of their 
own species (Saito et al., 2005). Indeed, human NKT cells generally express unique 
combinations of TCRs that consist of an invariant V24 chain preferentially paired with a 
V11 (Dellabona et al., 1994), while murine -GalCer-reactive CD1d-restricted NKT cells 
express invariant V14 paired with various V combinations (Gui et al., 2001). 
In contrast to species-restricted CD1 antigen-presenting molecules, both class I and class II 
MHC molecules are highly diverse among individuals as self-restricted elements presenting 
internally processed peptides as antigens, which can be recognized by the same MHC 
molecule-bearing TCR-expressing T cells with antigen-specificity established by 
intracellular gene rearrangements. Such gene rearrangements for the establishment of T cell-
mediated acquired immunity can be initiated through the combination of antigen-loaded 
MHC molecules plus appropriate co-stimulatory signals on DCs, although the induction of 
CD1-associated T cells does not require such co-stimulatory signals. Thus, co-stimulatory 
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signals appear to be required for the development of MHC molecule-restricted highly 
specific acquired immunity (Nakatsuka et al., 1999). Generally, CD8-positive T cells 
recognize the processed epitope peptide from internally synthesized proteins presented by 
class I MHC molecules, whereas CD4-positive T cells recognize epitope peptide from 
externally captured proteins in association with class II MHC (Dustin, 2009). The structures 
of the two distinct groups of antigen-presenting molecules, CD1 and class I MHC, closely 
resemble each other, having three regions of chains (1, 2, and 3) with non-covalently 
bound 2-microglobulin that may regulate the antigen-binding capacity of the presenting 
molecules (Kozlowski et al., 1991). However, although CD1-encoding genes are highly 
conserved and their structures are shared among species with limited polymorphism 
(Couedel et al., 1998), the class I MHC-encoding gene is highly diverse among individuals. 
So far, it has been reported that most innate NKT cells can be activated through CD1d and 
some T cells are activated through CD1c molecules on DCs (Cohen et al., 2009). Moreover, 
we have recently observed that live bacillus Calmette-Guerin (BCG)-activated DCs elicit 
innate effectors, such as NK cells, NKT cells, and T cells, to inhibit the growth of bladder 
carcinoma via IL-12 secretion (Higuchi et al., 2009). Collectively, DCs have the ability to 
manipulate innate effectors through CD1s and cytokines, as well as acquired effectors via 
MHC molecules to control internal tumors.   
4. DC subset and “cross-presentation” 
Recently, it has been demonstrated that two non-overlapping subsets of DCs are arranged to 
regulate internal immune responses in vivo; 33D1 (recognizing dendritic cell inhibitory 
receptor-2 (DCIR2))-positive and DEC-205-positive DCs (Dudziak et al., 2007). It has also 
been reported that in vivo targeting of DEC-205 with either poly(I:C) (Trumpfheller et al., 
2008) or an antibody specific for DC-NK lectin group receptor-1 (DNGR-1) (Sancho et al., 
2008) induced dominant Th1 immunity or potent CTL responses via cross-presentation, 
respectively. As indicated in Fig 5, it has turned out that the most suitable CTL epitope 
peptides within externally captured antigenic proteins are selected to present in association 
with class I MHC in DEC-205-positive DCs via cross-presentation (Moriya et al., 2010). 
We have shown that such cross-presentation, the shift of the antigen-presentation pathway 
from the class II MHC to class I MHC processing route for externally captured antigenic 
proteins, can be achieved by a bark-derived saponin-associated adjuvant, such as ISCOMs 
(Takahashi et al., 1990), cholera toxin (CT) (Wakabayashi et al., 2008), and BCG (Higuchi et 
al., 2009). We have also demonstrated (Fujimoto et al., 2004) that TLR3-signaling of DCs, 
previously loaded antigenic proteins, by double-stranded RNA, polyriboinosinic 
polyribocytidylic acid (poly(I:C)), which reflects a natural genetic product from a variety of 
viruses, can generate the cross-presentation. 
These results suggest that selective stimulation of DEC-205+ DCs in vivo may elicit effective 
acquired CD8+ CTL responses through Th1 dominancy by which protective immunity 
against tumors will be achieved even in the absence of externally added tumor antigens. We 
have recently established 33D1+ DC-depleted C57BL/6 mice obtained by treatment with 
33D1-specific monoclonal antibody (Moriya et al., 2010). As expected, 33D1+ DC-depleted 
mice, implanted with syngeneic B16-F10 melanoma cells into the dermis, showed apparent 
inhibition of already established tumor growth in vivo when subcutaneously (sc) injected 
with LPS after tumor implantation, in which serum IL-12 secretion that may be mediated by 
the remaining DEC-205+ DCs was markedly enhanced upon TLR4 signaling (Moriya et al., 
2010). Unexpectedly, LPS-stimulated 33D1+ DC-deleted tumor-bearing mice apparently 
produced H-2Kb-restricted epitope-specific CD8+ CTLs among tumor infiltrating 
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lymphocytes (TILs) against already established syngeneic tumor cells (Moriya et al., 2010). 
These findings indicate the importance and effectiveness of selective targeting of a specific 
subset of DCs, such as DEC-205+ DCs, for the activation of tumor-specific class I MHC 
molecule-restricted CD8+ CTLs without externally added tumor antigen stimulation in vivo. 
 
 
Fig. 5. New direction for tumor immuno-therapy. 
5. Concluding remarks: A new direction for tumor immunotherapy 
Because tumor epitope-specific CD8+ CTLs can be primed in vivo by immunization with 
epitope peptide-pulsed syngeneic DCs (Takahashi et al., 1993), most of the present works for 
the establishment of cancer immunotherapy have focused on identifying tumor-derived 
epitope peptides in each tumor; however, tumor-derived specific epitope peptides are 
generally very difficult to determine for most tumors because the structure of each epitope 
and its MHC cassette is highly diverse among individuals.  
Here, we would like to propose a new, promising strategy for the development of cancer 
immunotherapy; selective activation of DEC-205+ DCs in vivo. It should be noted that innate 
DEC-205+ DCs do not have memories and thus, repetitive intermittent stimulation is 
required to carry out this procedure. By this method, selectively activated DEC-205+ DCs 
recognizing newly appeared tumor cells capture antigenic molecules and present their 
antigenic epitopes in association with class I MHC via cross-presentation, and the presented 
epitope will prime acquired tumor-specific class I MHC molecule-restricted CD8+ CTLs that 
specifically recognize tumor cells with mutated genes and attack them. As far as we have 
examined, ISCOMs, CT and BCG have the capacity to selectively stimulate DEC-205+ DCs in 
vivo. Indeed, repetitive immunization with adjuvant alone shows apparent inhibition in the 
growth of syngeneic implanted tumors (Wakabayashi, A., Nakagawa, Y., Date, T., Tomita, 
Y., Shimizu, M, and Takahashi, H.; manuscript in preparation).  
In addition, as has been shown above, live BCG has the ability to activate innate effectors 
such as NK cells, NKT cells, and T cells to suppress the growth of early transformed 
tumors expressing MICA/MICB and stress-related substances via NKG2D (Higuchi et al., 
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2009). These results strongly suggest that we can manipulate appropriate immunity to 
control tumor cells by repetitive stimulation of DEC-205+ DCs with a BCG-derived 
substance. Now we should recall the name of Chisato Maruyama (1901-1992), a professor of 
the Department of Dermatology as well as the past President of Nippon Medical School in 
Japan, who had noticed that there were a very low number of cancer patients suffered from 
tuberculosis and established special substance from Mycobacterium tuberculosis as a cancer 
vaccine, named the “Maruyama Vaccine (SSM; special substance of Maruyama)” in 1944. 
The SSM has been widely used, particularly for various cancer patients in Japan; however, 
the actual mechanism of the SSM has been unknown until now. Thus, although a number of 
cases with excellent effects on cancer regression by SSM have been reported, many doctors 
are still suspicious of the effect of SSM. Here, it is proposed that new adjuvant therapy 
should be considered, including BCG or SSM that will activate internal innate immunity, 
particularly DEC-205+ DCs. 
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